Loading stock data…
$1.63+0.00 (+0.31%)
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States.
Regentis Biomaterials Ltd. in the Healthcare sector is trading at $1.63 with a market capitalization of $37M. Wall Street consensus targets $10.00 (1 analysts), implying a +513.5% move over the next 12 months. The stock is currently near its 52-week low of $1.23, remaining 49.7% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 21 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 |
|---|---|---|---|---|
| Total Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Operating Income | — | — | — | — |
| Net Income | — | — | — | — |
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen fo...